The ability of the immune system to identify and destroy nascent tumors, and to thereby function as a primary defense against cancer, has been debated for many decades. Recent findings by a number of investigators in both mouse models of cancer and humans with cancer now offer compelling evidence that particular immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor suppressor mechanisms. This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments.

Introduction
The immune system has three primary roles in the prevention of tumors. First, the immune system can protect the host from virus-induced tumors by eliminating or suppressing viral infections. Second, the timely elimination of pathogens and prompt resolution of inflammation can prevent the establishment of an inflammatory environment conducive to tumorigenesis. Third, the immune system can specifically identify and eliminate tumor cells on the basis of their expression of tumor-specific antigens or molecules induced by cellular stress.

The third process is referred to as tumor immune surveillance, whereby the immune system identifies cancerous and/or precancerous cells and eliminates them before they can cause harm. The idea that the immune system, which so effectively protects the host from microbial pathogens, might also recognize and destroy tumor cells was first discussed over a century ago and has recently been reviewed in detail (1). Despite tumor immune surveillance, tumors do develop in the presence of a functioning immune system, and therefore the updated concept of tumor immunoediting (1) is a more complete explanation for the role of the immune system in tumor development.

The tumor immunoediting concept is divided into 3 phases, designated elimination, equilibrium, and escape (2) (Figure 1). The elimination phase of cancer immunoediting is exactly the same process described in the initial theory of tumor immune surveillance, whereby the immune system detects and eliminates tumor cells that have developed as a result of failed intrinsic tumor suppressor mechanisms. The elimination phase can be complete, when all tumor cells are cleared, or incomplete, when only a portion of tumor cells are eliminated. In the case of partial tumor elimination, the theory of immunoediting is that a temporary state of equilibrium can then develop between the immune system and the developing tumor. During this period it is envisaged that tumor cells either remain dormant or continue to evolve, accumulating further changes (such as DNA mutations or changes in gene expression) that can modulate the tumor-specific antigens and stress-induced antigens that they express. As this process continues, the immune system exerts a selective pressure by eliminating susceptible tumor clones where possible. The pressure exerted by the immune system during this phase is sufficient to control tumor progression, but eventually, if the immune response still fails to completely eliminate the tumor, the process results in the selection of tumor cell variants that are able to resist, avoid, or suppress the antitumor immune response, leading to the escape phase. During the escape phase the immune system is no longer able to contain tumor growth, and a progressively growing tumor results.

This new concept of cancer immunoediting is a more satisfactory interpretation of various clinical and experimental data, which implicate a protective role for the immune system in tumor control. The observations that have led to the concept of tumor immunoediting are reviewed here, with a particular focus on experimental data from various mouse models of cancer and clinical experience.

Evidence for cancer immunoediting in animal models of cancer
Spontaneous tumor development in immunodeficient mice. The simplest approach for testing the role of the immune system in controlling tumor development is to remove specific components of the mouse immune system and monitor the mice for the development of tumors. Predominantly through the use of gene-targeted mice, this approach has demonstrated that a number of immune effector cells and pathways are important for suppression of tumor development (Table 1).

A role for the adaptive immune system in suppressing tumor growth was revealed when it was shown that 129/Sv RAG2-deficient mice, which lack both B and T cells, develop spontaneous adenocarcinoma of the intestine and lung (35% and 15%, respectively, of all mice analyzed) at 15–16 months of age, and an additional 50% of mice develop intestinal adenomas (3). Interestingly, when Rag2+/– mice were also deficient for STAT1, an important mediator of signaling induced by both type I and type II IFN, tumor incidence is further increased, and the spectrum of tumors broadens to include breast adenocarcinomas (~40% of mice), colon adenocarcinomas (~10% of mice), or both (~20% of mice) (3). Together, these results suggest that both the innate and the adaptive arms of the immune system are involved in the prevention of tumors, as mice lacking both IFN signaling and an adaptive immune system develop a broader spectrum of tumors than mice only lacking an adaptive immune system.

Mice lacking T cell and NK cell cytotoxic effector pathways have also been shown to develop spontaneous tumors. For example, mice that lack perforin, a cytotoxic molecule used by cytotoxic cells

Nonstandard abbreviations used: DMBA, 7,12-dimethylbenz[a]anthracene; IL-12R, IL-12 receptor; iMC, immature myeloid cell; MCA, methylcholanthrene; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; MSI, microsatellite instability; MSH, high MSH; NKG2D, NK group 2, member D; PCD, pannecrosis cerebellar degeneration; Tag, SV40 large T antigen; TIL, tumor-infiltrating lymphocyte; TPA, 12-O-tetradecanoylphorbol-13-acetate; TRAIL, TNF-related apoptosis-inducing ligand.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 117:1137–1146 (2007). doi:10.1172/JCI31405.
such as CD8+ T cells and NK cells to form membrane pores in target cells, develop lymphomas with age. These spontaneous lymphomas are of B cell origin, develop in older mice (>1 year of age) regardless of the mouse strain (4, 5), and, when transplanted into WT mice, are rejected by CD8+ T cells (4). B cell lymphomas also arise in mice lacking both perforin and β2m, and tumor onset is earlier and occurs with increased prevalence compared with mice lacking only perforin. In addition, B cell lymphomas derived from mice lacking both perforin and β2m are rejected by either NK cells or γδ T cells following transplantation to WT mice, rather than by CD8+ T cells (as in tumors derived from mice lacking only perforin), demonstrating that cell surface expression of MHC class I molecules by tumor cells can be an important factor in determining which effector cells mediate immune protective effects (6). Intriguingly, mutations in the gene encoding perforin have also been identified in a subset of lymphoma patients (7), although it is not clear whether this contributes to disease. Mice lacking the death-inducing molecule TNF-related apoptosis-inducing ligand (TRAIL) or expressing a defective mutant form of the death-inducing molecule FASL have also been shown to be susceptible to spontaneous lymphomas that develop with late onset (8, 9). These aging studies have clearly demonstrated a critical role for cytotoxic pathways in immunoregulation and/or immunosuppression of spontaneous tumor development in mice.

Several cytokine-deficient mice also develop spontaneous malignancies (5, 10, 11). In one study, approximately 50% of IFN-γ−deficient C57BL/6 mice were found to develop T cell lymphomas that
are predominantly disseminated lymphomas, although some cases of thymic lymphoma are also noted; interestingly, the susceptibility of Ifng<sup>−/−</sup> mice to T cell lymphomas is strain dependent (5). Furthermore, the spectrum of tumors observed in IFN-γ- and STAT1-deficient mice do not overlap, despite STAT1 being a crucial signaling molecule downstream of the IFN-γ receptor, indicating either that these molecules have some nonoverlapping activities or that the background strain has a modifying influence on tumor type. In addition, C57BL/6 mice lacking both IFN-γ and perforin display accelerated B cell lymphoma onset compared with perforin-deficient mice (5), indicating that IFN-γ has an important role in modifying the progression to B cell lymphoma in perforin-deficient mice. IL-12 and IL-18 are important IFN-γ–inducing cytokines; however, studies of aging have demonstrated that neither IL-12– nor IL-18–deficient mice display increased incidence of tumor development compared with WT mice (5).

A possible link between tumor immunity and autoimmune or infection-induced inflammation has been raised by several studies. Curiously, with age, 50% of mice lacking the β2 subunit of the IL-12 receptor (IL-12Rβ2) develop plasmacytomas or lung carcinoma in the context of the autoimmune disease immune complex mesangial glomerulonephritis (10). It is presently unclear why IL-12–deficient mice on the same genetic background as the IL-12Rβ2–deficient mice do not display either autoimmunity or spontaneous tumor development. Furthermore, mice deficient for both IFN-γ and GM-CSF have also been found to develop tumors with age; in this case, tumor development is associated with acute or chronic inflammatory lesions in a range of organs, and maintaining mice on the antibiotic enrofloxacin prevents (or at least delays) tumor onset (11). Collectively, these findings demonstrate that the immune system can suppress tumor development, but they do not constitute proof for tumor immunoeediting per se. The finding that antibiotic treatment could prevent tumor development in Gm-csf<sup>−/−</sup> Ifng<sup>−/−</sup> mice raises the possibility that rather than directly eliminating tumor cells, the immune system might prevent tumor growth by the timely elimination of infections, thereby limiting inflammation, which is known to facilitate tumor development (12). However, this finding cannot be generalized, as Rag2<sup>−/−</sup> and Rag2<sup>−/−</sup> Stat1<sup>−/−</sup> mice maintained on the same antibiotics and housed under strict specific pathogen–free conditions still display heightened tumor incidence despite testing negative for common pathogens with known links to malignancy and showing no signs of idiopathic inflammation (3).

Carcinogen-induced tumors in immunodeficient mice. In order to more readily study the role of the immune system in shaping tumorigenesis, researchers have turned to inducible tumor models, including carcinogen-induced tumors. The 2 most commonly employed carcinogen-induced tumor models are fibrosarcomas induced using methylcholanthrene (MCA) and skin papillomas induced by a combination of 7,12-di-methylbenz[a]-anthracene (DMBA) and 12-O-tetradecanoyl-phorbol-1-3-acetate (TPA). To date, a number of mice with defined immunodeficiencies have been tested for their susceptibility to carcinogens (Table 2).

<table>
<thead>
<tr>
<th>Strain</th>
<th>Description</th>
<th>Phenotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCID</td>
<td>Lack T and B cells</td>
<td>Mice develop T cell lymphomas (15% of mice)</td>
<td>118</td>
</tr>
<tr>
<td>Rag2&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack T and B cells</td>
<td>Mice develop intestinal adenosomas (−50%), or adenocarcinoma of the intestine (−35%) or lung (−15%); tumors detected at 15−16 months of age</td>
<td>3</td>
</tr>
<tr>
<td>Rag2&lt;sup&gt;−/−&lt;/sup&gt;Stat1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack T and B cells, deficient for type I and II IFN signaling</td>
<td>Mice develop intestinal adenosomas like Rag2&lt;sup&gt;−/−&lt;/sup&gt; mice (−20%), but also develop adenocarcinoma of the breast (−40%), colon (−10%), or breast and colon (−20%); tumors detected at 12−18 months of age</td>
<td>3</td>
</tr>
<tr>
<td>Perforin&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack perforin</td>
<td>Mice develop B cell lymphomas at 14−21 months of age</td>
<td>4</td>
</tr>
<tr>
<td>Ifng&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack IFN-γ</td>
<td>Mice develop lymphomas (predominantly T cell) at 13−19 months of age; effect is strain dependent (C57BL/6 are susceptible, BALB/c are resistant)</td>
<td>5</td>
</tr>
<tr>
<td>Perforin&lt;sup&gt;−/−&lt;/sup&gt;Ifng&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack both perforin and IFN-γ</td>
<td>Mice develop B cell lymphomas similar to those observed in perforin-deficient mice, but with earlier onset and increased frequency</td>
<td>5</td>
</tr>
<tr>
<td>Perforin&lt;sup&gt;−/−&lt;/sup&gt;B2m&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack both perforin and MHC class I expression</td>
<td>Mice develop B cell lymphomas similar to those observed in perforin-deficient mice, but with earlier onset and increased frequency</td>
<td>6</td>
</tr>
<tr>
<td>Lmp2&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Defective MHC class I antigen presentation</td>
<td>Mice develop uterine neoplasms (36%) by 12 months of age</td>
<td>119</td>
</tr>
<tr>
<td>Tra1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack TRAIL</td>
<td>About 25% of mice develop lymphomas late in life (&gt;400 days)</td>
<td>8</td>
</tr>
<tr>
<td>Gmcsf&lt;sup&gt;−/−&lt;/sup&gt;Ifng&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack GM-CSF and IFN-γ</td>
<td>Mice develop a range of malignancies, including lymphomas and solid tumors (predominantly ovarian choriocarcinoma, luteomas, or teratomas)</td>
<td>11</td>
</tr>
<tr>
<td>Ii12rb2&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Lack IL-12Rβ2</td>
<td>Mice develop plasmacytomas, lung carcinomas, or both (50%)</td>
<td>10</td>
</tr>
</tbody>
</table>
review series

Table 2
Carcinogen-induced tumors in immunodeficient mice

<table>
<thead>
<tr>
<th>Strain</th>
<th>Description</th>
<th>Phenotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rag2−/−</td>
<td>Lack T and B cells</td>
<td>Increased susceptibility to MCA-induced sarcomas, about 40% of sarcomas rejected following transplantation into WT recipients</td>
<td>3</td>
</tr>
<tr>
<td>Nude</td>
<td>Lack most T cells due to lack of thymus</td>
<td>Increased susceptibility to MCA-induced sarcomas, but dependent on strain; compared with sarcomas derived from WT mice, sarcomas from nude mice express higher levels of MHC class I and grow less aggressively when transplanted into WT hosts</td>
<td>14, 120</td>
</tr>
<tr>
<td>SCID</td>
<td>Lack T and B cells</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>13</td>
</tr>
<tr>
<td>Tcrb−/−</td>
<td>Lack γδ T cells</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>15</td>
</tr>
<tr>
<td>Tcra−/−</td>
<td>Lack γδ T cells</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>15</td>
</tr>
<tr>
<td>Cd1d−/−</td>
<td>Lack CD1d-restricted T cells</td>
<td>Increased susceptibility to MCA-induced sarcomas, some sarcomas rejected on transplantation into WT recipients</td>
<td>16</td>
</tr>
<tr>
<td>Ja18−/−</td>
<td>Lack semi-invariant NKT cells</td>
<td>Increased susceptibility to MCA-induced sarcomas, some sarcomas rejected on transplantation into WT recipients</td>
<td>16, 17</td>
</tr>
<tr>
<td>RAE1 transgenic</td>
<td>Defective killing through the NKG2D pathway</td>
<td>Increased susceptibility to DMBA/TPA-induced skin carcinogenesis</td>
<td>27</td>
</tr>
<tr>
<td>Perforin−/−</td>
<td>Lack perforin</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>19, 121</td>
</tr>
<tr>
<td>Tra1−/−</td>
<td>Lack TRAIL</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>122</td>
</tr>
<tr>
<td>Ifngr1−/−</td>
<td>Lack IFN-γR1</td>
<td>Increased susceptibility to MCA-induced sarcomas, reconstituting sarcomas with IFNγR1 facilitates their rejection by WT mice</td>
<td>21</td>
</tr>
<tr>
<td>Ifng−/−</td>
<td>Lack IFN-γ</td>
<td>Increased susceptibility to MCA-induced sarcomas and N-methyl-N-nitrosourea–induced lymphomas</td>
<td>25, 121</td>
</tr>
<tr>
<td>Stat1−/−</td>
<td>Deficient for type I and type II IFN signaling</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>3</td>
</tr>
<tr>
<td>Perforin+Ifng−/−</td>
<td>Lack both perforin and IFN-γ</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>121</td>
</tr>
<tr>
<td>Il-12p35−/−</td>
<td>Lack IL-12</td>
<td>Increased susceptibility to MCA-induced sarcomas and N-methyl-N-nitrosourea–induced lymphomas</td>
<td>25</td>
</tr>
<tr>
<td>Il-23p19−/−</td>
<td>Lack IL-23</td>
<td>Decreased susceptibility to DMBA/TPA-induced skin carcinogenesis</td>
<td>28</td>
</tr>
<tr>
<td>Il-12p40−/−</td>
<td>Lack IL-12 and IL-23</td>
<td>Increased susceptibility to MCA-induced sarcomas, decreased susceptibility to DMBA/TPA-induced skin carcinogenesis</td>
<td>16</td>
</tr>
<tr>
<td>Ifnar1−/−</td>
<td>Lack type I IFN signalling</td>
<td>Increased susceptibility to MCA-induced sarcomas</td>
<td>22</td>
</tr>
<tr>
<td>Cd80−/−Cd86−/−</td>
<td>Lack costimulatory molecules CD80 and CD86</td>
<td>Increased susceptibility to UV-induced skin carcinogenesis</td>
<td>123</td>
</tr>
</tbody>
</table>

restricted T cells, which bridge the innate and adaptive arms of the immune system, also have a role in suppressing MCA-induced fibrosarcomas. Mice that lack the potential TCR component Jx18 are unable to generate the semi-invariant Vγ14-Jx18–containing TCR expressed by NKT cells and show increased susceptibility to fibrosarcoma induction (16, 17). Interestingly, similar to immunogenic tumors from Rag2−/− mice, a portion of tumors arising in mice lacking Jx18 are rejected when transplanted into WT hosts (18), indicating that they are immunogenic and that the absence of NKT cells might contribute to the enhanced tumor development in Rag2−/− mice. Evidence that the innate immune system is also important in suppression of MCA fibrosarcomas was provided in mice chronically depleted of NK cells, since these mice display increased tumor incidence (16).

To further understand how the immune system suppresses fibrosarcoma growth, a number of mice deficient for specific immune effector molecules and pathways have been examined, including mice lacking perforin (19), TRAIL (20), IL-12 (16), IFN-γ (21), IFNAR1 (a component of the type I IFN receptor) (22), and NK group 2, member D (NKG2D) (23). Each of these mouse strains demonstrates enhanced susceptibility to fibrosarcoma induction, suggesting that cytotoxic cells (NK cells and CD8+ CTLs) use these pathways to suppress tumor growth in vivo. Interestingly, further investigation of this phenomenon revealed that tumor cells are important targets for the antitumor effects of IFN-γ (21), whereas the host hematopoietic system is the target of the antitumor effects of type I IFN (22), suggesting that the ability of type I IFNs to induce antitumor activity in immune cells might be the critical mode of action for this cytokine family.

This interpretation of the results regarding the role of IFN-γ in prevention of MCA-induced fibrosarcomas has not been universally accepted, however, with other researchers proposing that IFN-γ contributes to an inflammatory response that results in the encapsulation of injected MCA (a process referred to as a foreign body reaction), limiting its spread and thereby reducing its carcinogenic effects (24). However, the finding that Ifng−/− mice are more susceptible to lymphomas induced by the soluble carcinogen N-methyl-N-nitrosourea (25), where encapsulation of the carcinogen is not possible, is at odds with this concept. The finding that restoration of IFN-γ receptor 1 (IFN-γR1) expression in MCA-induced tumor lines from Ifng−/− mice leads to a delay in tumor growth or complete tumor rejection when such tumors are transplanted into WT mice also strongly suggests IFN-γ is not merely a driver for encapsulation of MCA.

A role for the immune system in regulating the development of DMBA/TPA-induced papillomas has also been investigated (Table 2). With the DMBA/TPA model, skin carcinomas are induced by the topical application of DMBA (the tumor initiator), followed by repetitive doses of TPA (the tumor promoter). In this model, lesions progress from benign papillomas through to metastatic squamous cell carcinomas, and the number and progression of the lesions is dependent on the mouse strain. While γδ T cells confer protec-
Lack TRAIL receptor DR5;

Collectively these data indicate that the NKG2D pathway is important in the control of carcinogen-induced tumors. IL-23 and LMP2 have demonstrated that the immune system can protect mice from oncogenic changes that it has acquired. The role of the immune system in suppressing tumors is likely to be dependent on the natural history of the individual tumor and the processes of elimination and immunoediting, along with a number of effector molecules, including perforin, TRAIL, and cytokines, including IFN-γ, type I IFNs, and IL-12. It is important to note that the effector cells and cytokines thought to be involved in elimination from DMBA/TPA-induced papillomas (15), αβ T cells seem to promote tumor progression in this model of carcinogenesis (26). One mechanism by which γδ T cells might regulate tumor development is through NKG2D recognition of the stress ligand retinoic acid early transcript 1 (RAE1), expression of which is induced in the skin by DMBA/TPA treatment. NKG2D-expressing dendritic epidermal γδ T cells can kill RAE1-expressing targets in vitro (15), but in transgenic mice expressing RAE1 in the skin, NKG2D expression is downmodulated on lymphocytes and consequently these mice are more susceptible to papilloma induction than are WT mice (27). Collectively these data indicate that the NKG2D pathway is important in the control of carcinogen-induced tumors. IL-23 and IL-12 are functionally related heterodimeric cytokines that both contain the IL-12Rβ1 subunit (although paired with distinct subunits) and activate distinct receptors that each contain the IL-12Rβ2 subunit. Interestingly, mice that lack functional IL-23 are resistant to tumor development, whereas mice that lack functional IL-12 develop increased numbers of papillomas compared with WT mice. In a broad panel of human tumors, the authors also found substantial upregulation of the mRNAs encoding both subunits of IL-23 and hypothesized that expression of IL-23 in human tumors has a causative role in promoting tumor growth. The effector cells and cytokines thought to be involved in elimination of IL-12–dependent pancreatic tumors (35). These results again confirm that these mice develop a lymphoproliferative disease similar to human adult T cell leukemia/lymphoma. When HTLV-Tax mice are crossed with Ifng−/− mice, tumor onset is accelerated, suggesting that IFN-γ has a protective effect in this model (33).

**Table 3**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Description</th>
<th>Phenotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>p53+/−Ifng1+/−; 129/Sv or 129/Sv × C57BL/6 background</td>
<td>Lack p53 and IFN-γR</td>
<td>Earlier tumor onset, broader spectrum of tumors compared with p53+/−; no change versus p53+/−</td>
<td>21, 24</td>
</tr>
<tr>
<td>p53+/−Tap1−/+</td>
<td>Heterozygous for p53 and lack TAP1</td>
<td>No change in tumor onset or spectrum versus p53+/− Tap1−/+</td>
<td>124</td>
</tr>
<tr>
<td>p53+/−Lmp2−/+</td>
<td>Heterozygous for p53 and lack LMP2</td>
<td>No change in tumor onset or spectrum versus p53+/− Lmp2−/+</td>
<td>124</td>
</tr>
<tr>
<td>p53+/−Perforin−/+</td>
<td>Heterozygous for p53 and lack perforin</td>
<td>Accelerated onset of B cell lymphoma</td>
<td>4</td>
</tr>
<tr>
<td>p53+/−Trail−/+</td>
<td>Heterozygous for p53 and lack TRAIL</td>
<td>Increased tumor incidence</td>
<td>8</td>
</tr>
<tr>
<td>Trail−/+HER2/neu transgenic</td>
<td>Lack TRAIL and transgenenic for HER2/neu (under MMTV promoter)</td>
<td>No change in mammary tumor onset, volume, or survival of host</td>
<td>8</td>
</tr>
<tr>
<td>Dr5+/−ApcMin+</td>
<td>Lack TRAIL receptor DR5; heterozygous for ApcMin</td>
<td>No change in colon adenocarcinoma onset</td>
<td>125</td>
</tr>
<tr>
<td>p53+/−Dr5−/−</td>
<td>Lack p53 and DR5</td>
<td>No change in tumor onset or spectrum</td>
<td>125</td>
</tr>
<tr>
<td>Ifng−/− HTLV-Tax transgenic</td>
<td>Lack IFN-γ and transgenic for human HTLV type I–derived Tax (under granzyme B promoter)</td>
<td>Accelerated leukemia and/or lymphoma onset</td>
<td>33</td>
</tr>
</tbody>
</table>

*ApcMin+, mutant multiple intestinal neoplasia (Min) allele of adenomatosis polyposis coli.*

**Genetic tumor models in immunodeficient mice.** Data supporting the ability of the immune system to suppress tumor development in genetic models of mouse cancer is less extensive. Several studies have demonstrated that the immune system can protect mice from malignancy induced by genetic means, whereas others have shown no effect (Table 3). Of the genetic tumor models, mice heterozygous for the tumor suppressor p53 (p53+/− mice) have provided the most convincing evidence for tumor immune surveillance, indicating a role for perforin (4), TRAIL (8), and IFN-γ (21) in immune control of tumor development. Transgenic expression of oncopogenes under the control of tissue-specific promoters has become a common technique to investigate the process of tumorigenesis; however, few of these studies have addressed the role of the immune system in delaying or preventing the development of tumors. A role for IFN-γ in suppressing tumor development has been observed in mice expressing the human T cell leukemia virus (HTLV) type 1–derived oncogene Tax under the control of a granzyme B promoter (HTLV-Tax transgenic mice); these mice develop a lymphoproliferative disease similar to human adult T cell leukemia/lymphoma. When HTLV-Tax mice are crossed with Ifng−/− mice, tumor onset is accelerated, suggesting that IFN-γ has a protective effect in this model (33). In a second transgenic tumor model, using the oncogene encoding the SV40 large T antigen (Tag), IFN-γ deficiency has no effect on tumor onset or the spectrum of tumors that develop (34); instead, tumor growth causes the skewing of T cell responses, with tumor-specific T cells producing TGF-β rather than IFN-γ. Similarly, CD8+ T cells have no effect on tumor development in the rat insulin promoter–Tag4 (RIP-Tag4) pancreatic tumor model, where Tag is expressed in the pancreas under the control of RIP, resulting in the development of pancreatic tumors (35). These results again confirm that the role of the immune system in suppressing tumors is likely to be dependent on the natural history of the individual tumor and the oncogenic changes that it has acquired.

**Summary of mouse models.** In summary, various cell types, including αβ and γδ T cells, NKT cells, and NK cells, have been implicated in the processes of elimination and immunoediting, along with a number of effector molecules, including perforin and TRAIL, and cytokines, including IFN-γ, type I IFNs, and IL-12. It is important to note that the effector cells and cytokines thought to be involved in elimination...
and immunoediting differ among models, demonstrating that the
success of immunoediting and the evidence of its occurrence varies
among experimental systems. Indeed, there are models in which the
immune system seems to have little influence on the rate of tumor
onset or progression (34) and models in which the immune system
has a distinct protective role, such as the carcinogen-induced tumor
models outlined above. The level of immune regulation and tolerance
(a state of nonresponsiveness to specific antigens) imparted by the
tumors in each of these models might explain, at least in part, why
in some cases the effect of subtracting immune elements on tumor
progression is less overt. Blocking these tolerance mechanisms might
reveal the true mechanisms of tumor suppressor immunity. Therefore,
to date, observations in mouse models are an indirect readout of
tumor elimination, and it has not yet been possible to observe the
establishment and subsequent immune-mediated regression (i.e.,
elimination) of an autochthonous tumor.

Evidence for the equilibrium phase of tumor immunoediting, dur-
ing which the tumor and antitumor immune response coevolve, is
least advanced and again indirect. MCA-induced fibrosarcomas from
mice lacking IFN-γ, IFNAR1, TRAIL, or T cells as well as lymphomas
from mice lacking perforin can be eliminated when transplanted into
immunocompetent recipients but grow progressively when trans-
planted into mice of the same genotype as that in which they arose.
These data suggest that the immune systemculpts the immuno-
genetic profile of evolving tumors, the exact process thought to occur
during the equilibrium phase of immunoediting. In contrast to the
equilibrium phase, abundant evidence exists for the escape phase of
immunoediting (see below), and the growth of tumors in immuno-
competent hosts is the most basic evidence that tumors can escape
immune control. More specific evidence for the escape phase comes
from studies in which an abortive, concurrent antitumor immune
response is detected in mice with progressive tumor growth.

Evidence for cancer immunoediting in humans

A number of clinical observations have provided evidence supporting
the notion of tumor immune surveillance in humans. The increased
risk of tumor development in immunosuppressed patients, instan-
tces of spontaneous tumor regression, and the appearance of tumor-
reactive T cells and B cells in relation to improved prognosis all point
to a role for the immune system in suppressing tumor growth.

Immunosuppressed patients. Immunosuppression (caused by either
primary or secondary immunodeficiencies) and therapy to prevent
transplant rejection are often associated with a heightened risk of
malignancy. Immunosuppression to prevent transplant rejection is
clearly associated with a heightened risk (3- to 100-fold increase) of
developing certain types of malignancy (36). These diseases are pre-
dominantly lymphomas; however, a range of solid tumors with no
known viral association also occur with increased frequency (36, 37).
In addition to these tumors in patients receiving immunosuppres-
sive drugs, a number of tumors (especially lymphomas) also occur
commonly in patients with primary and acquired immunodeficien-
cies; however, these are generally thought to have a viral etiology
(37). Perhaps a more convincing argument that cancer immunoedit-
ing does not occur in individuals who are immunosuppressed would
be if preexisting, dormant tumors grew after immunosuppression
commenced or if an existing tumor regressed following withdrawal
of immunosuppression. No studies have yet addressed these issues
in depth. In summary, although evidence from immunosuppressed
patients supports the theory of immunoediting, further investiga-
tion in this area is warranted, as the contributions of viral infection,
cytotoxic drugs, and persistent inflammation to tumorigenesis in
this setting must also be taken into consideration.

Microsatellite unstable human tumors. Some tumor types exhibit a par-
ticular type of genetic instability referred to as microsatellite insta-
bility (MSI), where defects in DNA mismatch repair mechanisms
lead to the duplication or deletion of short repeated sequences of
DNA known as microsatellites. Immunoediting seems to have an
important role in controlling genetically unstable colorectal tumors
in particular (38, 39). The infiltration of colorectal cancer cell nests
by CD8+ T cells is associated with a favorable prognosis (40), and
this association is further strengthened in cases where tumors
exhibit high levels of MSI (MSI-H) (38, 39, 41). Strikingly, MSI-H
tumors are often strongly infiltrated with lymphocytes, including
activated CD8+ T cells (41), and lymphoid follicles are often present
(39), indicative of a potent local immune response. The high rate of
mutation in MSI-H tumors has been shown to result in the genera-
tion of a number of novel tumor antigens that can be recognized
by B cells (42), CD4+ T cells (43), and CD8+ T cells (42). Together,
these findings suggest that the generation of antigenic peptides as a
result of genomic instability might result in the priming of a protec-
tive CD8+ T cell–mediated immune response in patients with MSI-H
colorectal cancers. Interestingly, this finding might not be unique
to colorectal cancers, as gastric medullary cancers, which frequently
exhibit MSI-H (41.2% of cases), are more prominently infiltrated
with lymphocytes than are nonmedullary gastric cancers, which
rarely display a MSI-H phenotype (1.6% of cases) (44). This trend
has also been observed in a study of resectable pancreatic cancer (45)
and in patients with non-Hodgkin lymphoma (46).

Human tumor-infiltrating lymphocytes. Tumor infiltration by T cells,
NK cells, or NKT cells has been associated with an improved prog-
osis for a number of different tumor types (2, 47–49). However,
tumor infiltration by some leukocytes, such as macrophages and
Tregs, can have a detrimental impact on tumor progression. An
association between favorable patient prognosis and tumor-infil-
trating lymphocytes (TILs) was first observed in patients with mel-
anoma (47, 48), where it was shown that patients with high levels
of CD8+ T cell infiltration survive longer than those whose tumors
contain low numbers of lymphocytes. Since then, various mel-
anoma-specific antigens have been identified, and the presence
of melanoma-specific T cells recognizing a range of different antigens
has been confirmed in various studies (reviewed in ref. 49). Taken
together, these studies indicate that melanoma TILs are often
tumor specific but respond to a wide range of different antigens.
However, it is important to note that the presence of melanoma-
specific CTLs in the blood is not predictive of survival, although the
presence of such cells among TILs can be an indicator of enhanced
survival in patients undergoing immunotherapy (50).

The plasma cell malignancy multiple myeloma (MM) might also
be a system in which immunoediting can be evaluated in a clinical
setting (51). The advantage of studying MM is that several stages
of disease have been identified, and disease progresses from a prema-
lignant state, known as monoclonal gammapathy of undetermined
significance (MGUS), through to terminal disease (52). The ability
to detect this premalignant phase of disease allows for immunologic
monitoring to assess the contribution of the immune system to pre-
venting and/or inhibiting progression to MM (53). Intriguingly, such
monitoring has revealed that T cells derived from the bone marrow
of patients with MGUS mount strong responses to autologous prema-
lignant cells; these responses are not detected in patients with MM
(53). These findings are consistent with a T cell response holding pre-
malignant cells in check (i.e., equilibrium) followed by the eventual failure of this response to control such abnormal plasma cell clones, resulting in the eventual transition to MM (i.e., escape).

**Paraneoplastic autoimmune syndromes.** In some cases, patients with tumors experience disease symptoms that are caused by the presence of a tumor but are not the result of local tumor growth. These diseases are referred to as paraneoplastic syndromes; if caused by activation of an immune response specific for self antigens expressed on tumor cells, they are known as paraneoplastic autoimmune syndromes. Paraneoplastic autoimmune syndromes may be caused by cross-reactivity between the antitumor immune response and neurologic antigens, and the onset of neurologic symptoms often precedes diagnosis of a previously undetected tumor. Interestingly, certain paraneoplastic autoimmune syndromes are associated with particular tumor types and particular autoantibodies (54), and the fine specificity of the antineuronal antibodies found in patients is often related to the type of tumor present (55, 56). For example, paraneoplastic cerebellar degeneration (PCD) is a neurologic syndrome that arises in some patients with gynecologic malignancies and Hodgkin disease; these patients typically exhibit high titers of Yo-specific autoantibodies (in the case of gynecologic tumors) or thioredoxin reductase 1-specific autoantibodies (in the case of Hodgkin disease) (57). Not only autoantibodies, but CTLs specific for antigens shared by tumors and Purkinje cells have been detected in the blood of PCD patients (58), and tumors from patients with PCD often show prominent infiltration with lymphocytes and plasma cells, which is indicative of a local immune response at the tumor site. In most cases, PCD is terminal, and the only patients that generally survive this condition are those that achieve complete tumor remission in response to therapy, once again demonstrating that the tumor is the probable driver of the immune response that is both self and tumor reactive. Interestingly, PCD symptoms can precede tumor diagnosis by a number of years (59), indicating that antitumor responses might be primed even by undetectable, microscopic tumors early in their evolution. It remains to be determined whether the antitumor immune response substantially delays tumor growth in patients with PCD, and such analysis is likely to be confounded by the lethality of the disease as a result of neurologic complications.

**Summary of human cancer immunoediting.** As is the case for mouse studies, varying evidence has been gathered supporting each of the distinct phases of human tumor immunoediting. The phenomenon of spontaneously regressing melanoma lesions accompanied by clonal expansion of T cells is presently the strongest evidence for the elimination phase of cancer immunoediting in humans (60–62). Generally speaking, however, cases of spontaneous tumor regression are rare, and it is presently unknown why regression is most common in melanoma. Spontaneous tumor regression accompanied by lymphocyte infiltration has also been noted for a number of other tumor types, including basal cell carcinoma (63), malignant lymphoma (64), Merkel cell carcinoma (65), mesothelioma (66), lung carcinoma (67), and congenital fibrosarcoma (68); however, the role of the lymphocyte infiltrate in tumor regression has not been established in these cases, and doing so is likely to be difficult due to the rarity with which such cases are observed.

Clinical evidence supporting the existence of the equilibrium phase of immunoediting is provided by a number of findings (53, 69, 70–75). First, the existence of an immune response to pre-malignant MGUS cells that eventually progress to MM is consistent with the equilibrium phase, with the immune system controlling, but not eliminating, MGUS cells that eventually evolve and progress to malignancy (53). Passive immunization with idiootype-specific antibody, in conjunction with either cytokine therapy or chemotherapy, can induce remission in some patients with low-grade B cell lymphoma; however, tumor cells are not completely eliminated and can be detected in the blood or bone marrow for up to 8 years following clinical remission (69). A role for the immune system in establishing long-term remission has also been suggested by studies of pediatric acute myeloid leukemia patients treated with either chemotherapy or chemotherapy combined with autologous bone marrow transplantation (70).

Clinical evidence suggests that tumors can remain dormant in patients for many years, and cases of relapse after long periods (at least 10 years) of tumor remission have been noted (71–73), making immune control with subsequent escape an intriguing possibility in these cases. In a similar vein, cases of transmission of tumors from organ donor to recipient have also been noted (74, 75). In such cases, it is possible that the tumor was being held under control by an immunologic mechanism in the donor and that transplantation of the organ into an immunosuppressed host allowed tumor outgrowth. Once again, although this is consistent with the theory of tumor immunoediting, other explanations for the growth of donor-derived malignancies are possible, such as alterations in tumor oncogene expression from a common cancer stem cell.

The escape phase is the best characterized of the three in both mice and humans. For example, the growth of melanomas clearly results in the priming of a tumor-specific immune response, even though this response is often insufficient to completely eliminate tumors (76). Similarly, the antitumor immune response seen in patients with paraneoplastic autoimmune syndromes indicates that an ongoing immune response is, in many cases, insufficient to control tumor growth, even when it is sufficient to destroy normal self tissues. How tumors escape immune control is now an active area of research, and the number of escape mechanisms reported is ever increasing.

**Failure of cancer immunoediting — tumor escape**

There is a considerable amount now known about tumor escape. In some cases it seems that the immune system is incapable of influencing tumor progression, but in many cases it seems that although the immune system prevents or delays tumor growth, it is eventually overwhelmed or evaded, and the tumor progresses. For example, tumors driven by expression of Tag develop in immunocompetent mice, even though the tumors express an antigen that is readily recognized by the immune system (34). Despite the inability of the immune system to control the growth of Tag-induced tumors, a Tag-specific immune response is often primed; however, this response declines, is overwhelmed, or is evaded, and tumors eventually progress. The failure of the immune system to control tumor growth in Tag-transgenic mice can occur at a number of levels, including the induction of central or peripheral tolerance. Central tolerance refers to the process by which self-reactive T cells are deleted or converted to a regulatory phenotype in the thymus (77). Clearly, however, central tolerance fails to eliminate all tumor- and/or self-reactive T cells, as is evident by the presence of tumor-specific T cells that recognize nonmutated self antigens (such as those belonging to the cancer/testis antigen family) in cancer patients (49).

In cases where tumor-associated antigens are not expressed in the thymus, or when T cells specific for tumor antigens escape central tolerance, tumor growth can induce T cell tolerance in the periphery. Peripheral tolerance can occur through a deletional mechanism, the induction of antigen unresponsiveness, or the skewing of
T cell functional responses, and evidence for each of these mechanisms has been observed in tumor models (34, 78). Often, immunotherapies that are able to induce protective responses when given before tumor challenge/onset (that is, prophylactically) fail against established tumors (35, 79–81). Importantly, in a number of cases, although tumor-specific immunity is compromised in tumor-burdened mice, there is often no generalized immune deficiency (82), indicating that tumors can specifically dampen down the induction of effective antitumor immunity. Concomitant immunity is one example where tumor growth clearly primes an antitumor immune response that ultimately fails to control the tumor’s growth: a mouse challenged with a given tumor will reject a subsequent challenge with the same tumor at a distant site, despite the fact that the initial tumor continues to grow (83–85). All of these examples collectively demonstrate that, in addition to central and peripheral tolerance, failure of antitumor immunity can be the result of factors within the local tumor environment. Similar findings have also been noted in clinical studies (86), and the lack of appropriate stimulation in the tumor microenvironment might cause the ineffective responses generated by TILs (87).

Many factors in the tumor microenvironment have been shown to contribute to tumor escape, including activation of T cells in the absence of appropriate costimulation, resulting in anergy (88); expression of T cell–inhibitory molecules such as B7–H1 (89), HLA-G (90), and HLA-E (91) by tumor cells; tumor antigen loss or downregulation of MHC molecules (92); the presence of both CD4+CD25+ Tregs and CD1d-restricted T cells that suppress antitumor immunity (93); soluble suppressive factors expressed by tumors, such as TGF-β (94–96), VEGF (97), IL-10 (98), and gangliosides (99); expression of indoleamine 2,3-dioxygenase (IDO) in tumors (reviewed in ref. 100); tumor resistance to cytotoxic pathways, as observed in tumors with mutations in the gene encoding FAS (101, 102), mutations in the gene encoding the TRAIL receptor death receptor 5 (DR5) (103), and overexpression of the antiapoptotic molecules FLIP and BCL-XL (104, 105); and expansion of immunosuppressive myeloid cell populations (106, 107). In the latter case, expansion of immature myeloid cell populations has been observed in a number of studies and is associated with profound suppression of T cell responses in both mice and humans (108, 109). Several tumor-derived cytokines have now been implicated in the expansion of immature myeloid cells (iMCs), including VEGF (110), IL-1β (111), and GM-CSF (112). The mechanism of iMC suppression is complex and seems to involve contributions from either iNOS (also known as NOS2) or arginase 1 (ARG1) (113–115). The signaling pathways activated by these molecules enable iMCs to inhibit T cell responses in various ways, including induction of apoptosis, inhibition of proliferation, or induction of a regulatory phenotype. Type 2 macrophages found at tumor sites have also been implicated in suppression of tumor immunity and seem to share some functional properties with iMCs (116). From these examples it can clearly be seen that by generating the appropriate environment, tumors can skew the immune response such that tumor growth, rather than elimination, is favored.

**Future directions**

We are armed with a lot of knowledge from mouse models of cancer regarding the various roles played by the immune system in tumor development; however, immunodeficient humans clearly have a far greater susceptibility to lethal viruses and pathogens than do immunocompromised mice in specific pathogen–free mouse facilities, and therefore the opportunities for observing increased spontaneous tumor formation in patients with mutations in specific genes encoding immune effector molecules are few. On the positive side, we might expect to see a wealth of new human genetic information generated by emerging high-throughput sequencing techniques, and this might enable a very rapid assessment of polymorphisms and mutations in immune pathway variations of large cancer patient cohorts that will confirm or deny the importance of key immune pathways in controlling human tumor development. The value of early detection, predicted risk, and prevention cannot be underestimated in this context.

It is also important in the future to clarify which particular immune cells are prognostic for each distinct type of cancer. Gene expression profiling and proteomics are going to have a key role in defining the major positive and negative immune indicators of human cancer progression. More also needs to be understood about the mechanisms required for the induction of a therapeutically relevant immune response in humans in the face of tumor escape. Indeed, even in mice, there is very little information about the extensive and continual coexistence of tumor cells, host stromal cell populations, and infiltrating leukocytes during any particular stage of tumor development. It is therefore important for tumor immunologists to gather a clearer molecular definition of the tumor microenvironment in real time, and perhaps only advanced imaging technologies will allow the specific cellular relationships to be properly discerned.

Immunotherapy is potentially synergistic with other treatment modalities, and approaches that trigger tumor cell death, alter the tumor microenvironment, reduce tolerogenic mechanisms, and stimulate immune responses might act in concert. An improved understanding of the immunobiology of cancer immunotherapy and a molecular definition of how tumors are shaped by this process will undoubtedly bring us closer to a more effective use of immunotherapy together with other conventional cancer treatments to prevent, control, and/or eradicate established cancer.

**Acknowledgments**

M.J. Smyth was supported by a National Health and Medical Research Council of Australia (NHMRC) Research Fellowship and Program Grant. J.B. Swann was supported by an Australian Postgraduate Research Scholarship. The authors would like to thank Robert Schreiber for helpful discussion.

Address correspondence to: Mark J. Smyth, Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, East Melbourne 8006, Victoria, Australia. Phone: 613-9636-3728; Fax: 613-9656-1411; E-mail: mark.smyth@petermac.org.

1145


